Payment overview · 2025
General Payments
$152.95
9 reported records · 6 companies
Healthcare provider profile · identity verified
Charles Joseph Wanker, MD
Allopathic & Osteopathic Physicians|Family Medicine · IOLA, KS · NPI 1609835446
Verified facts
What the public records show
CMS Open Payments records show Charles Joseph Wanker, MD received $152.95 in general payments during 2025 across 9 reported records.
Dexcom, Inc. accounted for 31.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 269 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $47.54 | 31.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.91 | 20.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.74 | 17.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.61 | 12.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.43 | 9.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $13.72 | 9.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $152.95 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $47.54 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.91 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $26.74 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.43 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 111 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 269 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 86 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
86 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
111 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
269 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
163 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1325 | 217 |
| Pantoprazole Sodium | Pantoprazole Sodium | 991 | 157 |
| Levothyroxine Sodium | Levothyroxine Sodium | 900 | 131 |
| Potassium Chloride | Potassium Chloride | 794 | 114 |
| Gabapentin | Gabapentin | 688 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 594 | 125 |
| Furosemide | Furosemide | 536 | 81 |
| Lisinopril | Lisinopril | 453 | 101 |
| Tamsulosin Hcl | Tamsulosin Hcl | 434 | 76 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 421 | 85 |
| Pregabalin | Pregabalin | 406 | 77 |
| Sertraline Hcl | Sertraline Hcl | 386 | 64 |
| Eliquis | Apixaban | 369 | 40 |
| Losartan Potassium | Losartan Potassium | 365 | 81 |
| Xarelto | Rivaroxaban | 336 | 40 |
| Metformin Hcl Er | Metformin Hcl | 326 | 65 |
| Trazodone Hcl | Trazodone Hcl | 325 | 47 |
| Carvedilol | Carvedilol | 322 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 294 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 286 | 53 |
| Omeprazole | Omeprazole | 284 | 59 |
| Bumetanide | Bumetanide | 283 | 35 |
| Jardiance | Empagliflozin | 269 | 47 |
| Buspirone Hcl | Buspirone Hcl | 263 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 263 | 74 |
| Myrbetriq | Mirabegron | 238 | 28 |
| Metformin Hcl | Metformin Hcl | 237 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 233 | 49 |
| Donepezil Hcl | Donepezil Hcl | 232 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 223 | 41 |
| Ozempic | Semaglutide | 222 | 41 |
| Prednisone | Prednisone | 222 | 80 |
| Alprazolam | Alprazolam | 220 | 44 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 203 | 28 |
| Allopurinol | Allopurinol | 201 | 30 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 199 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 189 | 69 |
| Famotidine | Famotidine | 185 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 166 | 54 |
| Alendronate Sodium | Alendronate Sodium | 166 | 32 |
| Simvastatin | Simvastatin | 166 | 35 |
| Trulicity | Dulaglutide | 163 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 162 | 35 |
| Mirtazapine | Mirtazapine | 153 | 30 |
| Methocarbamol | Methocarbamol | 152 | 34 |
| Ropinirole Hcl | Ropinirole Hcl | 148 | 17 |
| Montelukast Sodium | Montelukast Sodium | 140 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 131 | 82 |
| Quetiapine Fumarate | Quetiapine Fumarate | 126 | 17 |
| Topiramate | Topiramate | 122 | 21 |
| Lorazepam | Lorazepam | 116 | 17 |
| Tramadol Hcl | Tramadol Hcl | 113 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 112 | 38 |
| Farxiga | Dapagliflozin Propanediol | 111 | 23 |
| Levetiracetam | Levetiracetam | 111 | 13 |
| Aripiprazole | Aripiprazole | 109 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 106 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 104 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 103 | 26 |
| Spironolactone | Spironolactone | 102 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 101 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 99 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 98 | 15 |
| Meloxicam | Meloxicam | 98 | 29 |
| Finasteride | Finasteride | 97 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 96 | 15 |
| Sucralfate | Sucralfate | 96 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 93 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 22 |
| Tresiba Flextouch U-200 | Insulin Degludec | 93 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 89 | suppressed |
| Baclofen | Baclofen | 86 | 11 |
| Vraylar | Cariprazine Hcl | 86 | suppressed |
| Clonazepam | Clonazepam | 85 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 83 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 79 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 79 | 55 |
| Bupropion Xl | Bupropion Hcl | 75 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 25 |
| Memantine Hcl | Memantine Hcl | 72 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 72 | 11 |
| Propranolol Hcl | Propranolol Hcl | 69 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | suppressed |
| Tradjenta | Linagliptin | 65 | 12 |
| Digoxin | Digoxin | 62 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 45 |
| Cefdinir | Cefdinir | 59 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 59 | 16 |
| Levofloxacin | Levofloxacin | 58 | 35 |
| Solifenacin Succinate | Solifenacin Succinate | 58 | 18 |
| Nystatin | Nystatin | 56 | 35 |
| Tresiba Flextouch U-100 | Insulin Degludec | 56 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 52 | suppressed |
| Ketoconazole | Ketoconazole | 51 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 51 | 11 |
| Warfarin Sodium | Warfarin Sodium | 50 | 13 |
| Linzess | Linaclotide | 49 | 13 |
| Primidone | Primidone | 49 | suppressed |
| Novolog Flexpen | Insulin Aspart | 48 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 25 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 47 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 47 | 11 |
| Ezetimibe | Ezetimibe | 44 | 14 |
| Hydromorphone Hcl | Hydromorphone Hcl | 44 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | suppressed |
| Glimepiride | Glimepiride | 43 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 43 | 36 |
| Verapamil Er | Verapamil Hcl | 43 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 41 | suppressed |
| Atenolol | Atenolol | 40 | suppressed |
| Fluconazole | Fluconazole | 40 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 38 | suppressed |
| Lactulose | Lactulose | 38 | suppressed |
| Amoxicillin | Amoxicillin | 37 | 31 |
| Midodrine Hcl | Midodrine Hcl | 37 | 11 |
| Levemir Flexpen | Insulin Detemir | 36 | suppressed |
| Modafinil | Modafinil | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 29 |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 18 |
| Lovastatin | Lovastatin | 34 | 11 |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 13 |
| Cephalexin | Cephalexin | 31 | 25 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 23 |
| Nitroglycerin Patch | Nitroglycerin | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 11 |
| Celecoxib | Celecoxib | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 28 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 28 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 28 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | 11 |
| Acyclovir | Acyclovir | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Methimazole | Methimazole | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 16 |
| Ofloxacin | Ofloxacin | 24 | 22 |
| Xcopri | Cenobamate | 24 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 23 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 23 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Oxycontin | Oxycodone Hcl | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Anastrozole | Anastrozole | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Carbamazepine Er | Carbamazepine | 21 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 21 | suppressed |
| Movantik | Naloxegol Oxalate | 21 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 21 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 20 | 20 |
| Lubiprostone | Lubiprostone | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 18 | suppressed |
| Cartia Xt | Diltiazem Hcl | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Gemtesa | Vibegron | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 18 | 17 |
| Dutasteride | Dutasteride | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 16 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 16 | suppressed |
| Ertapenem | Ertapenem Sodium | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 15 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 12 |
| Lacosamide | Lacosamide | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Xtampza Er | Oxycodone Myristate | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 11 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Topiramate Er | Topiramate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $152.95 · 9 records | Dexcom, Inc. | AUSTEDO XR, Dexcom G6 Transmitter, FARXIGA, JARDIANCE, REXULTI, VRAYLAR | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error